Overview

Description

The Calvert International Diversity Research Index (CALIDI) is composed of companies that operate their businesses in a manner that is consistent with the Calvert Principles for Responsible Investment and are selected from the common stocks of the 500 largest publicly traded companies located in or tied economically to Europe and the common stocks of the 500 largest publicly traded companies located in or tied economically to other non-U.S. and non-European developed markets. As described in the Index Methodology and as determined by Calvert, Index components must meet certain criteria relating to leadership in having a diverse workforce and an equal and inclusive work culture, or demonstrate significant improvement in diversity practices. The Index is reviewed at least annually and rebalanced quarterly.
 

Historical Returns (%) as of Jun 30, 2024

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund’s current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative.
 

Index Facts

Price Ticker Symbol CALIDI
Total Return Ticker Symbol CALIDITR

Top 10 Constituents (%)2,3 as of Jun 30, 2024

Novo Nordisk A/S 4.50
Samsung Electronics Co Ltd 3.19
AstraZeneca PLC 2.26
Novartis AG 2.07
SAP SE 2.06
Roche Holding AG 1.99
LVMH Moet Hennessy Louis Vuitton SE 1.92
HSBC Holdings PLC 1.57
Siemens AG 1.37
Unilever PLC 1.33
Total 22.25

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.


Performance

Historical Returns (%) as of Jun 30, 2024

Past performance is no guarantee of future results. Investment return and principal value will fluctuate so that shares, when redeemed, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund’s current performance may be lower or higher than quoted. Returns are historical and are calculated by determining the percentage change in net asset value (NAV) with all distributions reinvested. Returns for other classes of shares offered by the Fund are different. Performance less than or equal to one year is cumulative.

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.


Portfolio

Index Statistics as of Jun 30, 2024

Median Market Cap $14.7B
Average Market Cap $117.6B
Price/Earnings Ratio 14.90
Price/Book Ratio 2.06
Number of Holdings 414

Sector Breakdown (%) as of Jun 30, 2024

Financials 24.17
Industrials 16.87
Health Care 16.47
Information Technology 11.69
Consumer Discretionary 8.99
Consumer Staples 6.66
Comm. Services 4.83
Utilities 4.30
Materials 3.60
Real Estate 1.22
View All
 

GICS Sector Breakdown (%)3 as of Jun 30, 2024

 

Index Constituents (%)3,4 as of May 31, 2024

Holding % of Index
Novo Nordisk A/S 4.27%
AstraZeneca PLC 2.26%
LVMH Moet Hennessy Louis Vuitton SE 2.03%
Novartis AG 1.95%
Roche Holding AG 1.83%
SAP SE 1.83%
HSBC Holdings PLC 1.64%
Royal Bank of Canada 1.52%
Unilever PLC 1.32%
Schneider Electric SE 1.31%
View All

Portfolio profile subject to change due to active management. Percentages may not total 100% due to rounding.


Literature

Literature

Index Rules and Methodology

Download Index Rules and Methodology - Last updated: May 17, 2024